Investment
Features
FeesSafety
Academy
More
Pluang+

Compare US Global Jets ETF (JETS) vs Novavax Inc (NVAX) Price & Performance

US Global Jets ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

US Global Jets ETF vs Novavax Inc — how do they compare? US Global Jets ETF trades at $30.68, while Novavax Inc trades at $8.02 (market cap $1.30B). The key difference: US Global Jets ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

JETSNVAX
Sector
Sector/ThematicHealth
52-Week High
$33.34$11.19
52-Week Low
$23.12$6.22
Market Cap
$1.30B
Enterprise Value
$800.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

US Global Jets ETF

JETS trades at $30.58, up 0.39% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF faces headwinds from rising fuel costs as U.S. airlines spent $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, July 2026), though falling oil prices recently provided some relief. Technical indicators show RSI levels in oversold territory at 24.66 for the 12-day period, suggesting potential buying opportunity.

The outlook remains cautious as airline profits face pressure from fuel volatility and Middle East conflict impacts. While lower oil prices offer temporary relief, the sector's cyclical nature and competitive dynamics with defense-focused ETFs present ongoing challenges. Investment opportunity exists for those betting on travel recovery, but risks from fuel price shocks and operational disruptions require careful monitoring.

Novavax Inc

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.

Returns comparison

Trailing returns across standard periods

About US Global Jets ETF

JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.

Read more on JETS

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX